Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Click to increase image sizeClick to decrease image size

Disclosure statement

D. J. Landsburg Consultant or advisory role: Morphosys, Karyoparhm, Celgene. Epizyme Research funding: Takeda, Curis, Triphase. Other remuneration: Karyopharm. S. D. Nasta Consultant or advisory role: Morphosys. Merck Research funding: Roche/Genentech, Millennium/Takeda, Pharmacyclics, ATARA, Forty Seven. J. N. Gerson Consultant or advisory role: Pharmacyclics, Genentech, AbbVie. Research funding: Loxo. J. Svoboda Consultant or advisory role: Seattle Genetics, Bristol-Myers Squibb, Pharmacyclics, Imbrium Therapeutics, Genmab, Adaptive Biotechnologies, ADC Therapeutics, Atara Biotherapeutics. Research funding: Celgene, Seattle Genetics, Pharmacyclics, Merck, Bristol-Myers Squibb, Incyte. Travel grants: Imbrium Therapeutics. E. A. Chong Consultant or advisory role: Novartis, Tessa Therapeutics, Bristol-Myers Squibb, Kite/Gilead. S. J. Schuster Consultant or advisory role: Celgene, Nordic Nanovector, Novartis, AbbVie, Acerta, Alimera Sciences, BeiGene, Juno Therapeutics, Loxo Oncology, Tessa Therapeutics, Genetech/Roche Research funding: Novartis, Pharmacyclics, Adaptive Biotechnologies, Merck, Genetech/Roche, Celgene, Juno Therapeutics, AbbVie, Incyte, TG Therapeutics, DTRM. S. K. Barta Consultant or advisory role: Monsanto Honoraria: Atara, Seattle Genetics, Janssen, Pfizer, Acrotech. Research funding: Seattle Genetics. K. W. Robinson No relevant conflicts of interest. M. E. Hughes Consultant or advisory role: AstraZeneca, Genzyme, Janssen, AbbVie, Karyopharm. Research funding: Acerta.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.